Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks St ...

NEW YORK, June 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biogen investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 13, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid= ...

LOS ANGELES, June 5, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are e ...

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv- 01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both ...

NEW YORK, June 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=82738&from=4 CLASS PERIOD: February 3, 2022 to February 13, ...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Biogen Inc. (NASDAQ: BIIB)? Did you purchase your shares between February 3, 2022 and February 13, 2024, inclusive? Did you lose money in your investment in Biogen Inc.? Do you want to discuss your rights? Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: B ...

文章核心观点 - 生物医药公司Biogen和航空公司Delta Flight Products将合作,了解残障乘客的出行需求,并开发更加包容和无障碍的航空旅行体验 [1][2][3] - 双方将在Cure SMA 2024年年会上与患有神经肌肉疾病的乘客互动,了解他们的出行需求和痛点,并展示Delta Flight Products研发的可以让乘客使用自己轮椅的座椅原型 [4][5][6] - Biogen长期致力于为罕见神经肌肉疾病患者提供独立生活支持,此次合作是为了推动航空无障碍化 [3] - Delta Flight Products致力于开发创新的航空座椅和舱内设计,其无障碍座椅原型获得2024年APEX创新大奖 [5][9] 公司信息 Biogen - 1978年成立的生物医药公司,专注于开发创新药物,为患者和股东创造价值 [7][8] - 在罕见神经肌肉疾病领域有深厚积累,此次合作是为了推动航空无障碍化 [3] Delta Flight Products - 为航空公司提供创新的机舱设计、技术系统、舱内设备等解决方案 [9] - 研发了可以让残障乘客使用自己轮椅的航空座椅,获得2024年APEX创新大奖 [5][9] 合作内容 - 双方将在Cure SMA 2024年年会上与患有神经肌肉疾病的乘客互动,了解他们的出行需求和痛点 [4][6] - 将利用这些洞见,开发更加包容和无障碍的航空旅行体验 [2][6]

Jeito Capital announces the acquisition by Merck & Co (NYSE:MRK) of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress achieved with Restoret™, EyeBio's novel late- phase candidate for diabetic macular edema, as well as a preclinical pipeline targeting retinal diseases - Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024 The acquisition by Merck & Co (NYSE:MRK), a global biopharmaceutical ...

A month has gone by since the last earnings report for Biogen Inc. (BIIB) . Shares have added about 7.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Biogen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Earnings Beat, Sales Miss Biogen’s first-quarter resul ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ: BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. secu ...